摘要
目的了解和掌握由中国自行研制的甲型H1N1流感疫苗的安全性与保护效果。方法采用描述流行病学、队列研究方法，对95244名首批次接种甲型H1N1流感疫苗的受种者，开展安全性与流行病学保护效果评价。结果95244名首批次接种甲型H1N1流感疫苗人员中，累计报告不良反应人数为193例，报告率为2．03‰；其中71．0％（137／193）的病例发生在接种后24h内。有81例不良反应确认与接种疫苗有关，其中78例（96．3％）属轻微反应。所有接种对象在接种后12周内未报告吉兰-巴雷综合征。甲型H1N1流感疫苗在不考虑接种率的情况下保护率可达到80．9％。结论甲型H1N1流感疫苗具有良好的安全性和流行病学保护效果。
Objective To evaluate the safety and epidemiological effects on the first mass vaccination program, using the China-made A （H1N1） influenza vaccine. Methods Descriptive epidemiology and cohort study design were used to assess the influenza A H1N1 vaccine on its safety and epidemiological effects. Results 95 244 subjects were immunized with A （H1N1） influenza vaccine. 193 adverse events were reported through AEFI Management System, with the Reported rates of AEFI as 2.03‰. Most of the adverse events （137/193,71.0%） happened during the first 24 hours after immunization was carried out. Of 81 adverse reactions confirmed to be related to immunization, with 78 （96.3%） showed mild reactions. No Guillain-Barre Syndrome related to vaccination was reported through the AEFI Management System vaccine could reach 80.9% when the coverage The epidemiological protection rate of A （H1N1） was not considered. Conclusion The A （H1N1） influenza vaccine showed a similar safety profile to seasonal flu vaccine. The vaccine demonstrated a good epidemiological effects against A （H1N1） influenza virus infection.
出处
《中华流行病学杂志》
CAS
CSCD
北大核心
2010年第5期481-484,共4页
Chinese Journal of Epidemiology
